These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Rusch V; Baselga J; Cordon-Cardo C; Orazem J; Zaman M; Hoda S; McIntosh J; Kurie J; Dmitrovsky E Cancer Res; 1993 May; 53(10 Suppl):2379-85. PubMed ID: 7683573 [TBL] [Abstract][Full Text] [Related]
67. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study. Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571 [TBL] [Abstract][Full Text] [Related]
68. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Da Silva L; Simpson PT; Smart CE; Cocciardi S; Waddell N; Lane A; Morrison BJ; Vargas AC; Healey S; Beesley J; Pakkiri P; Parry S; Kurniawan N; Reid L; Keith P; Faria P; Pereira E; Skalova A; Bilous M; Balleine RL; Do H; Dobrovic A; Fox S; Franco M; Reynolds B; Khanna KK; Cummings M; Chenevix-Trench G; Lakhani SR Breast Cancer Res; 2010; 12(4):R46. PubMed ID: 20604919 [TBL] [Abstract][Full Text] [Related]
69. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Tang X; Kadara H; Behrens C; Liu DD; Xiao Y; Rice D; Gazdar AF; Fujimoto J; Moran C; Varella-Garcia M; Lee JJ; Hong WK; Wistuba II Clin Cancer Res; 2011 Apr; 17(8):2434-43. PubMed ID: 21257719 [TBL] [Abstract][Full Text] [Related]
70. Heterogeneity and Clinical Effect of Epidermal Growth Factor Receptor in Primary Lung and Brain Metastases of Nonsmall Cell Lung Cancer. Xu S; Zhu J; Zhong D; Wang W; Wen Y; Zhang L; Jiang T J Surg Res; 2023 Mar; 283():674-682. PubMed ID: 36459860 [TBL] [Abstract][Full Text] [Related]
71. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Raso MG; Behrens C; Herynk MH; Liu S; Prudkin L; Ozburn NC; Woods DM; Tang X; Mehran RJ; Moran C; Lee JJ; Wistuba II Clin Cancer Res; 2009 Sep; 15(17):5359-68. PubMed ID: 19706809 [TBL] [Abstract][Full Text] [Related]
72. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990 [TBL] [Abstract][Full Text] [Related]
73. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686 [TBL] [Abstract][Full Text] [Related]
74. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Italiano A; Vandenbos FB; Otto J; Mouroux J; Fontaine D; Marcy PY; Cardot N; Thyss A; Pedeutour F Ann Oncol; 2006 Jun; 17(6):981-5. PubMed ID: 16524970 [TBL] [Abstract][Full Text] [Related]
75. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. Xu JM; Han Y; Duan HQ; Gao EM; Zhang Y; Liu XQ; Zhang JS; Toschi L; Galetta D; Azzariti A; Paradiso A J Cancer Res Clin Oncol; 2009 Jun; 135(6):771-82. PubMed ID: 19020901 [TBL] [Abstract][Full Text] [Related]
76. The HER family as therapeutic targets in colorectal cancer. Ye P; Wang Y; Li R; Chen W; Wan L; Cai P Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030 [TBL] [Abstract][Full Text] [Related]
77. [EGFR and HER2 gene expression status and their correlation in non-small cell lung cancer]. Zeng X; Wu SF; Zhou WX; Li DJ; Gao J; Liang ZY; Liu TH Zhonghua Bing Li Xue Za Zhi; 2006 Jul; 35(7):398-402. PubMed ID: 17069674 [TBL] [Abstract][Full Text] [Related]
78. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897 [TBL] [Abstract][Full Text] [Related]
79. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500 [TBL] [Abstract][Full Text] [Related]
80. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]